Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPGNASDAQ:ABUSNASDAQ:HCMNASDAQ:IMVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$24.80-2.2%$22.58$16.50▼$26.55$2.16BN/A59,833 shs5,409 shsABUSArbutus Biopharma$3.39-1.6%$3.27$2.71▼$4.73$650.23M1.5991,422 shs91,397 shsHCMHUTCHMED$13.78-0.6%$14.10$11.51▼$21.50$2.40B0.55100,430 shs30,373 shsIMVTImmunovant$14.74-1.0%$15.06$12.72▼$34.47$2.50B0.751.54 million shs242,117 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International+3.77%-0.82%+4.75%+33.21%+2,534,999,900.00%ABUSArbutus Biopharma+0.88%+6.83%+0.88%-0.29%+2.38%HCMHUTCHMED+4.76%+4.45%-8.58%-15.80%-25.72%IMVTImmunovant+5.60%+2.27%-2.17%-27.72%-49.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AN/AN/AN/AABUSArbutus Biopharma2.3128 of 5 stars3.50.00.00.03.82.50.6HCMHUTCHMED2.0112 of 5 stars3.02.00.00.02.20.01.9IMVTImmunovant2.2696 of 5 stars4.50.00.00.02.91.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.00BuyN/AN/AABUSArbutus Biopharma 3.00Buy$5.5063.45% UpsideHCMHUTCHMED 2.00Hold$19.0036.90% UpsideIMVTImmunovant 2.90Moderate Buy$38.33163.59% UpsideCurrent Analyst Ratings BreakdownLatest ABUS, IMVT, HCM, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025HCMHUTCHMEDHSBCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold4/22/2025IMVTImmunovantUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$38.00 ➝ $17.003/28/2025ABUSArbutus BiopharmaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/27/2025AAPGAscentage Pharma Group InternationalJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/20/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/20/2025IMVTImmunovantBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $33.003/19/2025IMVTImmunovantHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.003/10/2025IMVTImmunovantGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/4/2025IMVTImmunovantCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/3/2025IMVTImmunovantJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$20.003/2/2025IMVTImmunovantJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMixed ➝ Mixed(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$980.65M2.20N/AN/AN/A∞ABUSArbutus Biopharma$6.40M100.65N/AN/A$0.63 per share5.34HCMHUTCHMED$630.20M3.84$0.57 per share24.51$4.27 per share3.25IMVTImmunovantN/AN/AN/AN/A$2.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group InternationalN/AN/A0.00∞N/AN/AN/AN/AN/AABUSArbutus Biopharma-$72.85M-$0.41N/AN/AN/A-1,137.65%-68.18%-51.55%7/30/2025 (Estimated)HCMHUTCHMED$100.78MN/A0.009.51N/AN/AN/AN/A6/18/2025 (Estimated)IMVTImmunovant-$259.34M-$2.62N/AN/AN/AN/A-77.94%-69.82%6/4/2025 (Estimated)Latest ABUS, IMVT, HCM, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025IMVTImmunovant-$0.72-$0.64+$0.08-$0.64N/AN/A5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million3/27/2025Q4 2024ABUSArbutus Biopharma-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AABUSArbutus BiopharmaN/AN/AN/AN/AN/AHCMHUTCHMEDN/AN/AN/AN/AN/AIMVTImmunovantN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group InternationalN/AN/AN/AABUSArbutus BiopharmaN/A7.027.02HCMHUTCHMED0.072.812.68IMVTImmunovantN/A6.046.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AABUSArbutus Biopharma43.79%HCMHUTCHMED8.82%IMVTImmunovant47.08%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AABUSArbutus Biopharma20.30%HCMHUTCHMED3.60%IMVTImmunovant5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60087.07 millionN/AN/AABUSArbutus Biopharma90191.53 million181.91 millionOptionableHCMHUTCHMED1,760174.32 million168.04 millionNot OptionableIMVTImmunovant120169.86 million159.84 millionOptionableABUS, IMVT, HCM, and AAPG HeadlinesRecent News About These CompaniesImmunovant (NASDAQ:IMVT) Shares Gap Up on Earnings BeatMay 30 at 10:05 AM | marketbeat.comIMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in FocusMay 30 at 10:00 AM | zacks.comImmunovant (NASDAQ:IMVT) Posts Earnings Results, Beats Expectations By $0.08 EPSMay 30 at 9:49 AM | marketbeat.comImmunovant, Inc. Reports Strategic Progress and Financial ResultsMay 30 at 12:17 AM | tipranks.comImmunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The FenceMay 29 at 4:10 PM | msn.comImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025May 29 at 7:00 AM | globenewswire.comImmunovant (IMVT) to Release Earnings on WednesdayMay 29 at 1:27 AM | marketbeat.comH.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) StockMay 28 at 4:31 PM | msn.comImmunovant (IMVT) Expected to Announce Earnings on WednesdayMay 28 at 1:29 AM | americanbankingnews.comNuveen Asset Management LLC Sells 189,759 Shares of Immunovant, Inc. (NASDAQ:IMVT)May 26, 2025 | marketbeat.comBank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT)May 26, 2025 | marketbeat.comWoodline Partners LP Sells 772,251 Shares of Immunovant, Inc. (NASDAQ:IMVT)May 24, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Purchased by Two Seas Capital LPMay 23, 2025 | marketbeat.comRafferty Asset Management LLC Trims Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)May 22, 2025 | marketbeat.comIMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the FirmMay 21, 2025 | businesswire.comVestal Point Capital LP Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT)May 21, 2025 | marketbeat.comBrokerages Set Immunovant, Inc. (NASDAQ:IMVT) PT at $38.33May 21, 2025 | americanbankingnews.comTyro Capital Management LLC Has $3.75 Million Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)May 20, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by AnalystsMay 20, 2025 | marketbeat.comEnsign Peak Advisors Inc Cuts Position in Immunovant, Inc. (NASDAQ:IMVT)May 19, 2025 | marketbeat.comBNP Paribas Financial Markets Takes Position in Immunovant, Inc. (NASDAQ:IMVT)May 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABUS, IMVT, HCM, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$24.80 -0.55 (-2.17%) As of 11:16 AM EasternAscentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Arbutus Biopharma NASDAQ:ABUS$3.38 -0.06 (-1.60%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.HUTCHMED NASDAQ:HCM$13.78 -0.09 (-0.61%) As of 11:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.Immunovant NASDAQ:IMVT$14.74 -0.15 (-1.01%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
